Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29414619 | 1.00 | BCL2 (0.42) | BCL2SLC6A4SLC6A2HTR2CADRA1A | |
| SCHEMBL679 | 1.00 | BCL2 (0.42) | BCL2SLC6A4SLC6A2HTR2CADRA1A | |
| SCHEMBL29414628 | 1.00 | BCL2 (0.42) | BCL2SLC6A4SLC6A2HTR2CADRA1A | |
| SCHEMBL907577 | 1.00 | BCL2 (0.42) | BCL2SLC6A4SLC6A2HTR2CADRA1A | |
| Hydrochloric Acid SCHEMBL26647634 | 0.99 | BCL2 (0.41) | BCL2SLC6A4SLC6A2HTR2CADRA1A | |
| Bromide SCHEMBL29705204 | 0.99 | BCL2 (0.41) | BCL2SLC6A4SLC6A2HTR2CADRA1A | |
| Bromide SCHEMBL3623042 | 0.99 | BCL2 (0.41) | BCL2SLC6A4SLC6A2HTR2CADRA1A | |
| Acetic Acid SCHEMBL27702815 | 0.95 | SLC6A4 (0.42) | BCL2SLC6A4SLC6A2HTR2CADRA1A | |
| Oxalic Acid SCHEMBL21808124 | 0.95 | SLC6A4 (0.44) | BCL2SLC6A4SLC6A2HTR2CADRA1A | |
| Sulfuric Acid SCHEMBL26647671 | 0.95 | BCL2 (0.39) | BCL2SLC6A4SLC6A2HTR2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074750-B | Method for splitting citalopram intermediate 5-cyanodiol | 浙江华海药业股份有限公司 | 2022-03-25 | — | — | CN | claimed |
| EP-3219702-B1 | METHOD FOR RESOLUTION OF CITALOPRAM INTERMEDIATE 5-CYANOGEN DIOL | ZHEJIANG HUAHAI PHARMACEUTICALS CO LTD (CN) | 2021-05-05 | — | — | EP | claimed |
| US-10287240-B2 | Method for resolution of citalopram intermediate 5-cyano diol | Zhejiang Hushai Pharmaceuticals Co., Ltd. (CN) | 2019-05-14 | — | — | US | claimed |
| EP-3219702-A1 | METHOD FOR RESOLUTION OF CITALOPRAM INTERMEDIATE 5-CYANOGEN DIOL | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2017-09-20 | — | — | EP | claimed |
| US-20170240505-A1 | METHOD FOR RESOLUTION OF CITALOPRAM INTERMEDIATE 5-CYANO DIOL | ZHEJIANG HUAHAI PHARMACEUTICALS CO., LTD. (CN) | 2017-08-24 | — | — | US | claimed |
| CN-107074750-A | A kind of method for splitting the cyanogen glycol of Citalopram intermediate 5 | 浙江华海药业股份有限公司 | 2017-08-18 | — | — | CN | claimed |
| EP-2397461-A1 | Method for the manufacture of escitalopram | H. Lundbeck A/S (DK) | 2011-12-21 | — | — | EP | claimed |
| US-8022232-B2 | Method for manufacture of escitalopram | H. LUNDBECK A/S (DK) | 2011-09-20 | — | — | US | claimed |
| EP-2061753-B1 | METHOD FOR MANUFACTURE OF ESCITALOPRAM | LUNDBECK & CO AS H (DK) | 2011-08-03 | — | — | EP | claimed |
| US-7964742-B2 | including preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile intermediate by cyclization of 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymethyl)benzonitrile in the presence of a base | SUN PHARMA GLOBAL FZE (AE) | 2011-06-21 | — | — | US | claimed |
| US-20090069582-A1 | METHOD FOR MANUFACTURE OF ESCITALOPRAM | H. LUNDBECK A/S (DK) | 2009-03-12 | — | — | US | claimed |
| US-20080177096-A1 | PROCESS FOR PREPARATION OF CITALOPRAM AND ENANTIOMERS | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2008-07-24 | — | — | US | claimed |
| WO-2008059514-A2 | PROCESS FOR PREPARING ESCITALOPRAM | CADILA HEALTHCARE LIMITED (IN) | 2008-05-22 | — | — | WO | claimed |
| US-7112686-B2 | Process for the preparation of racemic citalopram and/or S-or R-citalopram by separation of a mixture of R-and S-citalopram | H. LUNDBECK A/S (DK) | 2006-09-26 | — | — | US | claimed |
| US-20040259940-A1 | Process for the preparation of racemic citalopram and/or s-or r-citalopram by separation of a mixture of r-and s-citalopram | H. LUNDBECK A/S (DK) | 2004-12-23 | — | — | US | claimed |
| EP-1412341-B1 | PROCESS FOR THE PREPARATION OF RACEMIC CITALOPRAM AND/OR S- OR R-CITALOPRAM BY SEPARATION OF A MIXTURE OF R- AND S-CITALOPRAM | LUNDBECK & CO AS H (DK) | 2004-12-08 | — | — | EP | claimed |
| JP-2004536093-A | — | — | 2004-12-02 | — | — | JP | claimed |
| CN-1520405-A | Process for the preparation of racemic citalopram and/or S-or R-citalopram by separation of a mixture of R-and S-citalopram | H��¡�±�������˾ | 2004-08-11 | — | — | CN | claimed |
| EP-1412341-A1 | PROCESS FOR THE PREPARATION OF RACEMIC CITALOPRAM AND/OR S- OR R-CITALOPRAM BY SEPARATION OF A MIXTURE OF R- AND S-CITALOPRAM | H. Lundbeck A/S (DK) | 2004-04-28 | — | — | EP | claimed |
| WO-2003000672-A1 | PROCESS FOR THE PREPARATION OF RACEMIC CITALOPRAM AND/OR S- OR R-CITALOPRAM BY SEPARATION OF A MIXTURE OF R- AND S-CITALOPRAM | H. LUNDBECK A/S (DK) | 2003-01-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069582-A1 | METHOD FOR MANUFACTURE OF ESCITALOPRAM | HTR1A, HTR4, TPH1 | BCL2 4123/4885SLC6A4 4/4885SLC6A2 23/4885 |
| US-10287240-B2 | Method for resolution of citalopram intermediate 5-cyano diol | TPH1, HTR4, HTR1A | BCL2 3672/4885SLC6A4 5/4885SLC6A2 54/4885 |
| US-20170240505-A1 | METHOD FOR RESOLUTION OF CITALOPRAM INTERMEDIATE 5-CYANO DIOL | TPH1, HTR4, HTR1A | BCL2 3672/4885SLC6A4 5/4885SLC6A2 54/4885 |
| US-20040259940-A1 | Process for the preparation of racemic citalopram and/or s-or r-citalopram by separation of a mixture of r-and s-citalopram | SLC6A4, SRR, SLC6A2 | BCL2 3390/4885SLC6A4 1/4885SLC6A2 3/4885 |
| US-20080177096-A1 | PROCESS FOR PREPARATION OF CITALOPRAM AND ENANTIOMERS | HTR1F, CYP2F1, CYP4F11 | BCL2 2195/4885SLC6A4 142/4885SLC6A2 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.